Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

Cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity are two major CAR T related toxicities. With the interventions of Tocilizumab and steroids, many patients can recover from severe CRS. However, some patients are refractory to steroids and develop life‐threatening cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jing, Deng, Biping, Ling, Zhuojun, Song, Weiliang, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Tan, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812291/
https://www.ncbi.nlm.nih.gov/pubmed/33314568
http://dx.doi.org/10.1111/jcmm.16176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812291/
https://www.ncbi.nlm.nih.gov/pubmed/33314568
http://dx.doi.org/10.1111/jcmm.16176

Ejemplares similares